Argenx
ARGX
#534
Rank
$38.14 B
Marketcap
$623.82
Share price
-0.35%
Change (1 day)
76.16%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -$62.51 Million USD

According to Argenx 's latest financial reports the company's current earnings are $1.85 Billion USD. In 2023 the company made an earning of -$0.31 Billion USD, an increase over its 2022 earnings that were of -$0.73 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -$62.51 Million-79.47%
2023 -$0.31 Billion-58.25%
2022 -$0.73 Billion
2019 -$0.2 Billion124.95%
2018 -$88.5 Million132.04%
2017 -$38.14 Million54.86%
2016 -$24.63 Million33%
2015 -$18.52 Million13.63%
2014 -$16.3 Million46.25%
2013 -$11.15 Million